SCHEMBL2775591

SCHEMBL2775591

Cc1ccc(C#N)c(-c2ccc(CO)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.43
CYP19A1 P11511 2/20 0.43
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
FFAR1 O14842 1/20 0.41
AR P10275 2/20 0.41
PDCD1 Q15116 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
MAOA P21397 2/20 0.39
PIM1 P11309 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
XDH P47989 2/20 0.39
ESR2 Q92731 1/20 0.39
S1PR1 P21453 1/20 0.38
FYN P06241 1/20 0.38
IKBKB O14920 1/20 0.37
CHUK O15111 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7575872 0.90 CYP19A1 (0.46) CYP19A1CYP11B1CYP11B2ARMAOA
SCHEMBL22560836 0.86 AR (0.51) CYP11B1CYP11B2ARMAOAPIM1
SCHEMBL7570228 0.83 FFAR1 (0.39) CYP19A1CYP11B1CYP11B2FFAR1AR
SCHEMBL7576136 0.81 AR (0.47) CYP19A1CYP11B1CYP11B2ARPDCD1
SCHEMBL21083736 0.80 CYP19A1 (0.46) CYP19A1CYP11B1CYP11B2PDCD1CD274
SCHEMBL2774861 0.80 CYP11B1 (0.48) CYP19A1CYP11B1CYP11B2FFAR1PDCD1
SCHEMBL15856477 0.79 ALDH1A1 (0.54) CYP19A1ARMAOAPIM1MAOB
SCHEMBL20658895 0.78 PDCD1 (0.45) CYP19A1CYP11B1CYP11B2ARPDCD1
SCHEMBL14003417 0.77 MAP2K4 (0.49) MAP2K4FFAR1PDCD1CD274FYN
SCHEMBL15832011 0.77 AR (0.51) CYP11B1CYP11B2ARMAOAXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501750-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
EP-2253630-A1 Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (JP) 2010-11-24 EP disclosed
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-03 US disclosed
EP-2151440-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-02-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF PCSK9, APOB, REN MAP2K4 3109/4885CYP19A1 400/4885CYP11B1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.